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Abstract 
Novel psychoactive substances (NPS) are new drugs of abuse. Over the last 10 years 50-100 new NPS 
have been detected for the first time each year. This has led to numerous deaths and challenges to 
healthcare providers and law-makers worldwide. We review pre-clinical studies of NPS and discuss 
how these studies have influenced legislative decisions. We focus on the UK legal system but include 
experiences from Europe. We reviewed manuscripts from 2008-2019 and have summarised the in-
vitro and in-vivo data on NPS, highlighting how these studies define pharmacological mechanisms 
and how they might predict ‘harm’ in humans. We found that only a small percentage of NPS have 
been examined in pre-clinical studies. Most pre-clinical studies of NPS focus on basic 
pharmacological mechanisms (46% of studies reviewed) and/or addictive liability (32%) rather than 
toxicity and ‘harm’ (24%). Very few pre-clinical studies into NPS include data from chronic dosing 
schedules (9%) or female rodents (4%). We conclude that pre-clinical studies can predict harm to 
humans, but most of the predictions are based on basic pharmacology rather than demonstrated 
toxicity. Some of these studies have been used to make changes to the law in the UK and Europe and 
perhaps, because of the paucity of toxicology data, most NPS have been placed in the highly 
dangerous ‘schedule 1’ or Class A category in the UK. We suggest that in-silico studies and high 
throughput toxicology screens might be the most economical way forward to rapidly screen the 
health harms of NPS. 
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1. Introduction  
Over the last decade, the drug scene has completely changed. In 2018 a ‘new’ Novel Psychoactive 
Substance (NPS) was reported to the European Commission Early Warning System every week with 
55 NPS reported in total. This is a much lower number than that reported in 2013-2015 (1). Despite 
the fact that the observed decline could have resulted from many factors such as international 
legislation or possible “lack of innovation”, many substances continued to resurge globally (1), 
indicating a new established illicit repertoire. Other approaches employed to capture the true number 
of NPS that are globally available includes using a 24/7 web crawler such as the ‘NPS.Finder®’ (2). This 
novel approach showed that the online scenario includes over 4000 unique psychoactive molecules 
of interest to psychonauts, a number that is approximately four-fold the number being reported to 
the known NPS databases (European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) and 
United Nations Office on Drugs and Crimes (UNODC)) (2).  
In the UK, NPS were originally known as “psychoactive drugs which are not prohibited by the United 
Nations Single Convention on Narcotic Drugs or by the Misuse of Drugs Act 1971, and which people in 
the UK are seeking for intoxicant use” (3). They were therefore initially emerging to circumvent 
international legislation. In the UK, the Psychoactive Substances Act (PSA) 2016 broadly defined them 
as “any substance, which is capable of producing a psychoactive effect” (4), covering any substance 
that is not controlled by the Misuse of Drugs Act 1971. Under the latter definition, the UK Home Office 
issued a forensic strategy to test for the psychoactivity of an unknown substance (5), which is key for 
prosecution in the UK (6). In this respect, in-vitro testing was recommended by the ACMD (Advisory 
Council on the Misuse of Drugs) to prove if a substance is psychoactive. This mandates positive 
receptor and functional assays at one or more of the following receptors or transporters: CB1 
(cannabinoid receptor type 1), GABAA (γ-aminobutyric acid A receptor), 5HT2A (serotonin 2A receptor), 
NMDA (N-methyl-D-aspartate receptor), µ-opioid receptor and monoamine transporters (dopamine, 
serotonin, norepinephrine). However, since in-vitro testing may not be suitable for all substances (e.g. 
nitrous oxide and solvents), in-vivo testing has been recommended as an alternative. In vitro testing 
can predict human doses for stimulants and psychedelics, for example (7) but cannot easily predict 
human pharmacokinetics or brain penetration. Information may also be retrieved from scientific 
literature if in-vitro/ in-vivo testing cannot be performed (5) . 
Despite the apparent decline in the numbers of emerging NPS, research is lagging behind the rapid 
changes in this complex market. Case reports including clinical and forensic cases, and emergency and 
mental health admissions have shown that NPS are associated with unpredictable acute adverse 
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events, serious harms and even deaths (8). Knowledge of long-term effects following chronic use of 
NPS is lacking and systems that capture harms resulting from NPS are still patchy (9).  
Animal models have been previously validated and have played pivotal roles in pre-clinical research 
informing the neurobiological, psychopathological, behavioural and etiological aspects underlying 
drug addiction and acute/ chronic drug use (10 - 11). They have long been used to inform on the 
various phases of drug addiction including drug self-administration patterns, behavioural criteria that 
define vulnerability to drug abuse, conditioned place preference, craving and relapse, escalation of 
drug-taking, impulsivity, continued drug-taking despite adverse drug reactions, physical dependence 
and other neuropsychopathological aspects, which lead from a “voluntary” drug-taking to 
“compulsive” behaviours (10 - 14). Furthermore, Preclinical studies have contributed to understanding 
the toxicity spectrum associated with some traditional drugs of abuse including knowledge of  
neurotoxic effects seen with amphetamines (15) and MDMA (16), as well as non-neurological toxic 
effects such as MDMA-induced heart-valve issues (17)  and bladder problems associated with 
ketamine use (18). 
Recent reviews of NPS included studies which focussed on toxicity such as Assi et al., (2017) (19) who 
reviewed the literature between 2007-2015 for NPS toxicity, yielding 20 studies and concluded that 
the harmful effects of NPS could be severe or lethal. Tracy et al., 2017 (20) summarised NPS-induced 
health harms as deduced from available clinical data, while Evans-Brown and Sedefov (2018) reviewed 
the NPS risk assessment protocols across the EU (21). 
Here we review the pre-clinical studies of NPS over the last 10 years and summarise the findings from 
the main classes of NPS. We then examine the evidence that has been used in changing the legal status 
of NPS focussing on the UK with some examples from Europe.  
2. Materials and Methods 
A literature search was performed on PubMed and Web-of-Science (Medline), from January 2008 to 
November 2019. We employed database-specific search strategies with multiple keywords utilising 
word truncation/ wild card symbols and index terms as appropriate for each database. The literature 
search was not undertaken using individually named NPS due to their large number, up to 4000 by 
some estimates (2); consequently, not all pertinent studies may be identified. 
Each identified article was categorised into the following topics (based on title and abstract review): 
pharmacological and behavioural experiments (preclinical studies), human studies (clinical), detection 
and identification (forensic), legal status (legal), epidemiology, comments, letters, replies (reports) 
and reviews.  
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2.1 Search strategy and study selection NPS 
The following search terms were used in PubMed: 
(((((((legal high[Title/Abstract]) OR novel psychoactive substance[Title/Abstract]) OR new 
psychoactive substance[Title/Abstract]) OR bath salt[Title/Abstract]) OR designer 
drug[Title/Abstract]) OR plant food[Title/Abstract])) AND ((((((((((in-vitro[Title/Abstract]) OR in-
vivo[Title/Abstract]) OR cell[Title/Abstract]) OR slice[Title/Abstract]) OR anesthetized[Title/Abstract]) 
OR anaesthetised[Title/Abstract]) OR rat[Title/Abstract]) OR mouse[Title/Abstract]) OR 
murine[Title/Abstract]) OR rodent[Title/Abstract]) NOT review 
In Web-of-Science, we selected the Medline database with the following search terms: 
TI= (legal highs* or novel psychoactive substance* or new psychoactive substance* or bath salt* or 
designer drug* or plant food*) and MH=(in-vivo* or in-vitro* or cell* or slice* or anesthetised* or rat* 
or mouse* or rodents*). 
The literature search yielded 335 articles from both PubMed and Web-of-Science (Figure 1). Additional 
22 articles were found deemed to be relevant. Fourty-seven articles were excluded due to duplicates. 
Three-hundred-and-ten articles were screened for inclusion, and 66 were excluded they were deemed 
irrelevant. Two-hundred-and-five articles were screened for eligibility, and 136 were excluded in the 
final screening because they did not meet the following criteria: 1) NPS was not a major outcome; 2) 
the article was a clinical study; 3) the article was a forensic study; or 4) the article was a review. In 
total, 108 journal articles from the original search were used in the final analysis (Figure 1). 
<Figure 1 is about here> 
3. Summary of results from NPS searches 
After excluding ineligible manuscripts, we found 55 animal (in-vitro or in-vivo) studies examining 
cathinones, 25 studies on stimulants, only eight studies on synthetic cannabinoid receptor agonists 
(SCRAs) and 20 studies on ‘other’ NPS. We have grouped the types of studies undertaken into four 
broad areas: 1) behavioural models of addiction; 2) neurochemistry/ neuropharmacology of addiction; 
3) toxicity; and 4) cognitive dysfunction.  
3.1. Cathinones 
The most commonly studied cathinone was MDPV (3,4-Methylenedioxypyrovalerone) (25 studies 
(45%)), followed by mephedrone and methylone (16 studies (29%)) and α-PVP (α-
pyrrolidinovalerophenone) (7 studies (13%)). All other cathinones studied were only examined in 
three or fewer manuscripts: (Table 1). Most studies examined these substances in models of addiction 
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such as increased locomotion, locomotor sensitisation, conditioned place preference, drug self-
administration, increased intracranial brain stimulation and withdrawal effects; there were 31 (56%) 
such studies. The next most common type of study were neurochemical assays associated with 
dopamine, serotonin or noradrenaline; these mostly examined changes in these transmitter levels or 
effects on their transporters; there were 17 such studies (31%). The next most common type of study 
was related to toxicity: cell death, cell toxicity, reactive oxygen species (ROS) or hyperthermia and 
there were 11 such studies (20%). Three studies (5%) examined cardiovascular issues such as blood 
pressure or heart rate, one looked at hepatotoxicity, three (5%) looked at cognitive deficits such as 
memory impairment and one study (2%) examined the effects of cathinones on rodent offspring. Only 
2 studies (4%) examined chronic effects of cathinones and only 2 studies (4%) reported using female 
rodents. 
<Table 1 is about here> 
3.2. Stimulants. 
The most studied NPS stimulants were TFMPP (3-Trifluoromethylphenylpiperazine), N-
benzylpiperazine and 4,4’-DMAR (4,4'-Dimethylaminorex), which were all studied in four manuscripts 
(16%). The other stimulants were only studied in three or less manuscripts (Table 2). The NPS 
stimulants were mostly studied using neurochemical assays at dopamine, serotonin or noradrenaline 
systems (16 studies (64%)) with six studies (24%) examining toxicity or hyperthermia, three studies 
(12%) looked at the behavioural effects using models of addiction and a single study used assays 
related to the cardiovascular system. Thus, similar to the cathinones, the vast majority of studies 
examined either behavioural or neurochemical indices of addiction and very few looked at acute toxic 
effects. No studies examined chronic effects of stimulants and no studies reported using female 
rodents. 
<Table 2 is about here> 
3.3. SCRAs  
There have been very few pre-clinical studies on SCRAs over the last 10 years with only 10 or so SCRAs 
examined in eight studies. These include JWH- and CP-compounds while AKB48 was the most studied 
SCRA (3 studies (38%)). Despite the lack of studies, it is clear that the types of assay differ from both 
the cathinone and stimulant research. In the SCRA manuscripts, five studies (63%) examined cell 
toxicity, five studies (63%) examined their neuropharmacology, one study looked at cardiovascular 
effects and one study looked at models of addiction. Thus, in contrast to the cathinone and stimulant 
Page | 7  
 
studies, there was only one study looking models of addiction and proportionally more studies 
examined toxicity (Table 3). 
We note previous studies on SCRAs from outside our search period (Jan 2008 - Dec 2018), for example 
Randall et al., (2004) (22). In this article, we focussed only on studies from the last 10 years, which 
include the so-called third generation SCRAs (23 - 24). 
<Table 3 is about here> 
3.4 Other NPS 
There are relatively few studies on ‘other’ NPS (20 studies) with the most studied drugs being 
methoxetamine and 25B-NBOMe (both 4 studies, 20%). Most of the assays used are to examine the 
neuropharmacology of the drugs (12 studies (60%)) with only one manuscript examining effects of the 
drugs in models of abuse. Four studies (20%) looked at the toxicity of these drugs, two studies (10%) 
found cognitive dysfunction, one found bladder and renal toxicity and one looked at cardiovascular 
effects (Table 4). 
<Table 4 is about here> 
3.6. Overview of pre-clinical data on NPS (more formal and supported) 
Taken together we can see that most recent studies on NPS examined the reinforcing effects or 
addictive liability of NPS, whether through behavioural models (32%) or neurotransmitter changes 
such as dopamine levels (46%). Taking NPS for their rewarding effects is one of the motivations for 
use, other reasons for using NPS including self-medicating to treat withdrawal symptoms from other 
drugs or the availability when traditional drugs are scarce or supplementing the illicit drug use by 
trying to induce synergistic or additive effects. From a legislative point of view, it might be useful to 
know if a drug was more or less addictive and this criterion is used by the EU for banning NPS (25). 
Further, more resources, whether it be policing, research, healthcare or education could be targeted 
at those NPS predicted to be more addictive. The next most common type of study examined cell 
toxicity (24%). This is useful as highly toxic substances should clearly be banned and this criterion is 
also used by the EU. Interestingly, the effects of these drugs, which might result in acute 
hospitalisation, for example cardiotoxicity, seizure activity, hyperthermia, or death, have hardly been 
studied at all in NPS (all <5%).  
Only 4% of studies included female rodent samples and only 9% included chronic dosing studies. The 
age range of most studies was appropriate with most (72%) using rodents, which were adolescent or 
in early adulthood (100 – 299 g) and only 22% of studies examining older rodents (> 300 g). 
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4. Predictive validity of NPS tests in animal tissue 
As detailed above, when NPS started flooding the market over the last decade or so, pre-clinical tests 
were exploited to compare these substances to their traditional counterpart, describing them as 
“cocaine-like” or “amphetamine-like” substances(26 - 27). Unlike known illicit substances such as 
methamphetamine and MDMA (3,4-methylenedioxymethamphetamine), the pharmacology related 
to emerging NPS is scarce and may not suitably be extrapolated from existing knowledge. For example, 
when the risk assessment of 2C-I (2,5-dimethoxy-4-iodophenethylamine) was carried out in 2003, a 
“speculative comparison” was made with the phenethylamine analogue 2C-B (2,5-dimethoxy-4-
bromophenethylamine) and the amphetamine analogue DOB (2,5-dimethoxy-4-
bromoamphetamine), as they both have similar chemical structures to 2C-I but with a bromine instead 
of iodine. It was deemed inappropriate to compare or extrapolate data related to the structurally 
similar MDMA, PMA (paramethoxyamphetamine) and 4-MTA (4-methylthioamphetamine) due to the 
absence of the 2,5-dimethoxy functional group (28). 
The validity of animal models in understanding the harmful effects of illicit substances in humans is 
well established and therefore, can provide a predictive validity for NPS-related harms. For instance, 
ketamine has been associated with bladder toxicity (29). Similar to ketamine, animal models showed 
significant bladder and renal toxicity in rodents following the administration of 30 mg/kg 
methoxetamine intraperitoneally (30). Symptoms included “inflammatory cell infiltration, tubular cell 
necrosis, glomerular damage” and “increased micturition frequency bladder dysfunction”(30) (31).  
Benzofurans such as 5‐APB (5‐(2‐aminopropyl)benzofuran), 5‐APDB (5‐(2‐aminopropyl)‐2,3‐
dihydrobenzofuran), 6‐APB (6‐(2‐aminopropyl)benzofuran), 6‐APDB (5‐(2‐aminopropyl)‐2,3‐
dihydrobenzofuran), 4‐APB (4‐(2‐aminopropyl)benzofuran), 7‐APB (7‐(2‐aminopropyl)benzofuran), 5‐
EAPB (5‐(2‐ethylaminopropyl)benzofuran) and 5‐MAPDB (1‐(2,3‐dihydrobenzofuran‐5‐yl)‐N‐
methylpropan‐2‐amine) are all structurally similar to MDMA (32). Similar to MDMA, they were found 
to activate the 5‐HT2B receptor (Dawson et al., 2014), which induces heart valve fibrosis (33 - 35)  and 
inhibit dopamine transporters (DAT) (36 - 37).  
MDPV (3,4-methylanedioxypyrovalerone) is a cathinone derivative with a nitrogen atom in the 
pyrrolidine ring and a 3,4-methylenedioxy group on the phenyl ring similar to MDMA (38). In-vitro and 
in-vivo rodent models showed that MDPV blocks the dopamine and norepinephrine transporters in a 
similar way to the pyrovalerone analogues. It is more potent at both the dopamine and 
norepinephrine transporters and less potent blocking serotonin in a similar way to cocaine (38 - 39). 
The potent blockade of dopamine and epinephrine stipulates that MDPV has the potential of inducing 
a high risk of abuse/ addiction, and life-threatening cardiovascular stimulation including tachycardia 
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and hypertension respectively, more than cocaine (38 - 39). This was consistent with in-vitro data 
assessing blood-brain barrier permeability, in-vivo microdialysis and in-vivo locomotor activity testing 
in rats (26, 38 – 39). 
One problem with pre-clinical studies is whether or not the toxic dose or concentration from the pre-
clinical study reflects clinical doses. There is a wealth of literature on MDMA toxicity in the 5-HT 
system, but this has been criticised because the doses needed to show neurotoxicity in animals may 
be far above the clinically relevant doses (40). 
Taken together, we can see that pre-clinical studies can be used to predict health harms. Some 
researchers have gone a step further, using in-silico studies to predict addictive liability of NPS. The 
benzofurans 5-APB and 5-MAPB were predicted to bind to DAT in a similar way to MDMA (37),  while 
ketamine-like NPS dipehidine and methoxphenidine were predicted to bind differently at DAT (41).  
5. Evidence used in UK legislation and in Europe 
5.1. Evidence used in the UK 
In the UK, the government takes advice on issues around drugs of abuse from the ACMD who risk 
assess emerging substances and issue subsequent recommendations (42). The ACMD also advises the 
government on the control of drugs and drugs requiring a temporary class drug order. In their first 
NPS report, on BZP (benzylpiperazine), they recommended that the drug and some of its 1-phenyl and 
1-benzyl derivatives be brought under the Misuse of Drugs Act (1971): “The ACMD considers that the 
harms and misuse of BZP and substituted piperazines (identified in Annex 4) are commensurate 
with Class C, under schedule 2, part III, of the Misuse of Drugs Act (1971); and should be scheduled 
under Schedule I of the Misuse of Drugs Regulations (2001) (having no recognised medicinal use).” 
This decision was based on a report by the EMCDDA (43). In this report there is evidence from 
pre-clinical studies in the 1970s and 80s that BZP had addictive liability and had similar properties 
to amphetamine or MDMA. These studies were undertaken as the drug was being examined for 
antidepressant effects. More recent data from the 2000s is focused on human use and in 
particular BZP use in New Zealand where it was a popular party drug. This data suggest that the 
drug should not be used by people susceptible to seizures or in those with cardiac conditions. It 
is difficult to attribute blame to a particular drug in many of the human studies as in most cases 
the drug takers, although being shown to have BZP in their systems, may have consumed 
numerous other substances. Thus, although the UK government banned BZP, as it was obliged to 
do by the European Commission, the direct evidence for toxicity was limited because much of the 
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data came from polydrug users. Nevertheless, its known pharmacological profile and its 
suspected effects on humans clearly merited some sort of control. 
In another early publication, this time ‘advice’ to the then Home Secretary Theresa May, on D2PM 
(Ivory wave) which “…typically cause prolonged agitation (lasting up to 5 days after drug use 
which is sometimes severe, requiring physical restraint), paranoia, hallucinations and myoclonus 
(muscle spasms/twitches)”, the ACMD recommended that there was an immediate ban on the 
import of 2-DPMP. This ‘advice’ was followed a year later by a ‘report’ on desoxypipradrol (3), the 
ACMD could again rely on data from previous studies as desoxypipradrol had been tested for 
narcolepsy. After considering information from hospital emergency rooms, published research, 
drug company data and coroners reports the advice was to bring desoxypipradrol and its 
associated drugs D2PM and 2-diphenylmethylpyrrolidine under the Misuse of Drugs Act (1971). 
The clinical evidence used to ban desoxypipradrol included three studies: a case report of a man 
who had taken D2PM with agitation and chest pains (44); five case reports have shown the 
presence of D2PM rather than desoxypipradrol and the victims exhibited signs of agitation, 
anxiety and insomnia but not any sympathomimetic toxicity (45); two case reports involving  
polydrug abusers, again presented with agitation, anxiety and insomnia but without increased 
heart rate, hypertension or hyperthermia (46). None of these studies actually confirmed 
desoxypipradrol use. Recent preclinical data has shown that desoxypipradrol was more potent 
than cocaine at inhibiting dopamine reuptake (47). Perhaps the best evidence to ban 
desoxypipradrol came from a report by Ciba-Geigy in the 1950s showing that desoxypipradrol 
tended to have a much lower LD50 (lethal dose, 50%) in animals than amphetamine or 
methamphetamine. 
The ACMD went on to provide a number of reports and advice on various NPS including 
cathinones (2010), methoxetamine (2012), benzofurans (2013), N-BOMe, AH-7921 (3,4-dochloro-
N-[[1-(dimethylamino)cyclohexyl]-benzamide), tryptamines, MT-45 (1-cyclohexyl-4-(1,2-
diphenylethyl)-piperazine) and 4,4’DMAR (all 2014), MPA (methiopropamine) (2016), third 
generation SCRAs (2016), methylphenidate-like NPS (2017) and 2-4-dinitrophenol (2019). Not all 
NPS had a previous history as a potential medicine, where there were previous pre-clinical and 
clinical studies on the compound. For example, see the EMCDDA risk assessments where the 
pharmacodynamic profiles of emerging substances such as SCRAs on other pharmacological 
targets other than CB1 is very limited. This is particularly true for AB-CHMINACA (N-(1-amino-3-
methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide), ADB-CHMINACA (N-
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(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide), 5F-
MDMB-PINACA (5F-ADB or methyl-2-{[1-(5-fluoropentyl)-1H-indazole3-carbonyl]amino}-3,3-
dimethylbutanoate),  CUMYL-4CN-BINACA (1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-
carboxamide) and many more . 
In May 2016, the UK government adopted a different approach aimed at limiting the supply of 
NPS and capturing substances that escaped the Misuse of Drugs Act 1971 (4) rather than on 
evidence-based risk assessments. However, as explained above, implementation of the Act is 
highly reliant on in-vitro databases of a representative set of molecules (6). This is quite limited 
given the time taken to develop these libraries and the limitations of these libraries when facing 
emerging previously-unseen substances. 
Take together we can see that pre-clinical evidence has previously played an important role in 
deciding to ban NPS in the UK and continues to support the implementation of the new legislation. 
The clinical evidence, mostly case reports, is somewhat unreliable due to polydrug use and co-
morbities, amongst other issues. Much of the preclinical evidence only suggested potential harms, 
rather than showing actual toxicity, and is dogged by the obvious need to extrapolate from 
animals to humans. 
5.2. Overview of evidence used in Europe  
In Europe, the process has been quite similar to that described above for the UK. The EMCDDA 
have published numerous reports and advice on NPS. These started with BZP (2007, 2009), Spice 
(2009), 4-MA (2012), MDPV, methoxetamine, AH7921, 25I-NBOMe, 4,4’-DMAR and MT-45 (2014) 
and more recently a number of reports on SCRAs and synthetic opioids. In their report (25) on 
“New Psychoactive Substances in Europe; Legislation and Prosecution; Current challenges and 
Solutions” they describe four broad attempts of member countries controlling NPS. First, by trying 
to control NPS under laws around medicinal products, but this was thrown out by the Centre for 
Justice for the European Union on the grounds that NPS were not medicines. Second, some 
countries have tried to use existing laws around existing consumer safety laws. Third, existing 
drug laws have been modified by using group definitions of some NPS. Fourth, new laws have 
been developed, for example the UK PSA 2016 described above. In these new laws the criteria 
used to define a psychoactive substance is often different and most use an element around harm 
or threat to health (including dependence) and a criterion that the drug has a psychoactive effect. 
Clearly, without pre-clinical data, and preferably human data, it is difficult to say with any 
certainty that an NPS has a psychoactive effect or could cause harm. Some countries also define 
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psychoactivity quite clearly in their legislation with Ireland requiring ‘significant’ mental 
disturbance or change and Hungary and Portugal requiring the NPS to have “effects similar to 
established drugs of abuse and a likelihood to cause dependence” (25).   
The EMCDDA have published 22 risk assessments for NPS. The most recent assessment will be 
used as an example. This was a risk assessment of the synthetic opioid cyclopropylfentanyl. The 
EMCDDA and Europol examined the available information based upon the following criteria: “(1) 
the amount of the material seized; (2) evidence of organised crime involvement; (3) evidence of 
international trafficking; (4) analogy with better-studied compounds; (5) evidence of the potential 
for further (rapid) spread; and (6) evidence of cases of serious intoxication or fatalities.” They 
reported a ‘pharmacological description’ of a few studies mostly limited to examining the effects 
of this NPS at µ-opioid receptors in-vitro where it was shown to be more potent than morphine 
or fentanyl (48) and a single animal study, in mice, suggesting analgesic properties (49). The health 
risks were suggested to come from accidental overdose and no acute or chronic toxicity studies 
had been carried out, nor had its dependence liability been examined. It was assumed that this 
NPS would have toxicity similar to morphine or fentanyl. The report described deaths associated 
with cyclopropylfentanyl, which included 78 in Sweden, three in the UK, one in Norway and over 
100 in the USA (48), albeit in nearly all cases users had recently used multiple drugs. The report 
was submitted to the European Commission and Council of the European Union, who decided 
that cyclopropylfentanyl should be subject to control measures across member states. Thus, the 
EU banned this NPS based on very little direct pharmacological or toxicology data and include 
information on criminality as a criterion to ban the substance. 
6. Conclusions  
Clearly it would be beneficial to know as much as possible about each NPS, however scientific curiosity 
needs to be tempered by the reality of the current drug scene where the vast majority of problems 
are caused by relatively few established drugs of abuse. It is possible that some NPS may join these 
established drugs of abuse as major players in the morbidity and mortality associated with 
recreational drug use and it is these most commonly used NPS that we should focus upon. However, 
horizon scanning for the next MCAT/mephedrone or Spice/SCRA is also important. We have 
summarised the pre-clinical data on NPS above and given examples of these data being used in UK 
and EU legislation. It is reasonable to ask if the changes in legislation have been evidence-based? Nutt 
and colleagues have published in this area for established drugs of abuse and concluded that UK and 
Australian scheduling of drugs of abuse is not particularly evidence-based. They highlight the easy 
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access to nicotine and alcohol, despite these drugs being ranked as highly dangerous. On the other 
hand, Ecstasy, LSD and magic mushrooms, despite being ranked very lowly on the danger scale, are 
both schedule 1, class A drugs in the UK (50). It is difficult to say that the UK blanket ban (4) on 
psychoactive substances is evidenced-based. The vast majority of NPS have not been examined at all 
while those that have been examined, as described above, tend to be looked at for their addictive 
effects rather than toxic effects. In addition, studies examining the long-term effects of NPS are very 
rare and these types of studies would be best placed from which to extrapolate health harms. 
Nevertheless, the ban appears to be having some of the desired effects as recent evidence suggests 
fewer problems associated with NPS (5). The ACMD and EMCDDA reports are generally evidence-
based but limited to a relatively small number of NPS or families of NPS and a relatively small number 
of supporting studies. Having said that, given the very large number of NPS (up to 4000 by some 
estimations (2),  there is little chance of all of these drugs being looked at in detail. The best that we 
can realistically hope for is putting many of these drugs through some high throughput screens for 
receptor/ transporter binding (51 - 52) and high throughput toxicity assays (53). An alternative 
approach is in-silico testing i.e. modelling the effects of the drugs at receptors or transporters of 
interest. We have done this for some ketamine-like NPS including diphenidine and methoxphenidine 
and MDMA and some similar NPS including 5-APB and 5-MAPB (37, 41). We also suggest that future 
studies focus more on measures of toxicity (e.g. neurotoxicity, vasoconstriction, hepatotoxicity, 
seizures and hyperthermia) as this has clearly been overlooked with most studies focussing on rodent 
behavioural or neurochemical (dopamine) measures of dependence. Finally, there are very few pre-
clinical studies using tissues from female rodents. This is important as drug effects do show sexual 
differentiation (54). Thus, in order to get an accurate overview of NPS pharmacology, more studies 
using female tissue are needed. 
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Table 1. Cathinones. 




Samples Assay Main results 
Dias da Silva, 




Metaphedrone 31 nM to 
10 mM 
1 μM,10 μM, 




150 – 250 g Hepatocytes Cytotoxic 
assays 
↑ autophagic and apoptotic/necrotic 
mechanisms 
Gannon, B.M. 










275 –300 g  Self-
administration 
Methylone + caffeine results in an 
enhanced reinforcing effectiveness 
compared to methylone alone 
Luethi, D. et 












↑ potency to inhibit NA uptake with 
Methylone compared with DA and 5-HT 
uptake. 
↓ transporter inhibition 
Potencies with N-demethylation of 
methylone. 
= NA and DA uptake 
inhibition potencies with O-
demethylenation of methylone and 
MDPV. 
 
Blough, B.E. et 







300 - 400 g Synaptosomes  Compounds substituted at the 2-
position (ortho) were primarily 
dopaminergic 
Compounds 
substituted at the 4-position (para) 
were found to be more serotonergic 












All cathinones showed cell membrane 
integrity, depleted ATP levels, and 
increased mitochondrial superoxide 
concentrations 





α-PVP and naphyrone impaired basal 
and maximal cellular respiration 
Gerecsei, L.I. 
et al., 2019 
(60) 




↑ apoptotic cells in the pallium and in 
the subpallium 
↓NR2B expression in the treated group 
Kolesnikova, 




α-PVP 1, 5, 25 and 
50 mg/L for 
20 min 
1, 5 and 10 
mg/L for 7 
days 
Zebrafish   Drug exposure 
HPLC 
α-PVP psychostimulant effects at 5, 25 
and 50 mg/L 
Hypolocomotion and repeated 
withdrawal after a 7-day chronic 
treatment  
Mayer, F.P. et 













   Human urine Monoamine 
transporter 
assays 
↑ potency at SERT with S-enantiomers 
of nor-mephedrone and 4-OH-
mephedrone than the corresponding R-
enantiomers. 
↓ effectivity as releaser at SERT with R-
enantiomers. 
Eshleman, A.J. 







and 1 stimulant 







Most α-pyrrolidinophenones had high 
hDAT potencies and selectivities 
4-Cl-ethcathinone 
and 3,4-methylenedioxy-N-
propylcathinone had higher hSERT 
selectivity 
Benzofurans had low hDAT selectivity 
and were releasers at hSERT 
Yoon, H.S. et 




α-PVT 20 mg/kg 
(i.p) 




↑ locomotor sensitization 
↓ phosphorylation levels of GSK3β 










MDPV 3 mg/kg (i.p) Male Sprague-
Dawley rats 
8 weeks 











↑ stereotypies and open arm entries in 
the elevated plus maze with acute 
administration 
 ↑ ΔFosB with chronic administration  
Colon-Perez, 












Evans rats  




















↓ strength of correlated neural activity 
at 1 h  
↓ striatal DAT at 24 h and caused a 
shift in subcellular levels and 
distribution of DAT, TH and VMAT2 
 ↓ ICSS thresholds at 1 h 
↑ 50 kHz USV calls at 1 h  
↓ social interactions 
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Oliver, C.F. et 













275 – 300 g 
 




AMD3100 reduced MDPV-induced 
locomotor activation, conditioned place 
preference and modulated MDPV-






Luethi, D. et 















 4-MA, and MMAI entactogenic effects 
and 3-MMC, 5-IT, and N-methyl-2-AI 
have stimulant-type properties  
Siedlecka-
Kroplewska, 





















↑ intracellular production of reactive 
oxygen species 
↑ formation of autophagic vacuoles 
↓ level of p62/SQSTM1 protein 
Zwartsen, A. 





























↓ the weighted mean firing rate and 
weighted mean burst rate 
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Gerecsei. et 






























↓ birth rate, survival of offspring, and 
maternal care in the drug-treated 
animals 
 
↑ locomotor activity of the pups in the 
MDPV treated group 
 
Gannon, B.M. 






















both enantiomers of MDPV and 
α -PVP function as highly effective 
reinforcers. 
Philogene-
Khalid, H.L. et 

















↑ break points rats trained to self-
administer R-MEPH and greatest rates 
of 50 kHz ultrasonic vocalization than S-
MEPH  
Nelson, K.H. 






















α-PVP induced dose-dependent taste 
avoidance as well as significant 
increases in time spent on the drug-



















20 – 25 g  Two-bottle 
choice 
procedures 
↑MDPV preference solution when was 
paired with quinine but no with water 
↑ escalate consumption with chronic 
(10 days) access at 0.30 mg/mL MDPV 







↑ CPP at 0.30 mg/mL MDPV with a 
magnitude similar to the preference 
observed following intraperitoneal 
administration of MDPV 
↑ locomotor activity at 0.1–1.0 mg/mL 
MDPV 
Lantz, S.M. et 






Rats  PC12 cells Cytotoxicity 
assay 
↑death cell after CP exposition  
CP alters mitochondrial function and DA 
and 5-HT levels 
Luethi, D. et 











Bupropion, MDPV, mephedrone and 
naphyrone are mitochondrial toxicants 
Grecco, G.G. 


















↑Cmax and AUC0-∞, and the longest 
t1/2 In the plasma with pentylone  
↑Cmax and AUC0-∞ in the CNS with 
methylone and butylone 
Elmore, J.S. et 
al., 2017 (79) 
10.1038/npp.2
016.213 
Methylone 3, 6, and 12 
mg/kg 
Male Sprague-
Dawley rats  








↑ motor activation at 12mg/kg 
methylone 
↓ core temperature at 3 and 6 mg/kg 
but showed biphasic effects at 12mg/kg 
 
Methylone acted as a fully efficacious 
substrate-type releaser at DAT, NET, 
and SERT 
↑ brain extracellular dopamine and 5-
HT in-vivo 
McLaughlin, 














comparable potency at DAT but the 
latter compound was more potent at 
NET and SERT 
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Schindler, 














  Telemetry 
 
S(+) enantiomer appeared to mediate 
the cardiovascular effects of MDPV 
 
Berquist, M.D. 


















  Locomotor 
activity 
 
Locomotor responses sensitize to MDPV 
and to certain mixtures of MDPV and 4-
MMC following repeated dosing 
 
Schindler, 






















MDPV self-administration was acquired 
rapidly compare with methylone. 
MDPV (0.1 and 0.3 mg/kg) increased 
extracellular dopamine while i.v. 
methylone (1 and 3 mg/kg) increased 
extracellular dopamine and 5-HT 
 
Valente, M.J. 
























MDPV and Pentedrone were the most 
cytotoxic. 
All cathinones triggered significant 
caspase activation and apoptosis 
Colon-Perez, 




MDPV 0.3, 1.0, or 
3.0 mg/kg 
Male Long 
Evans rats   






MDPV dose-dependently reduced 
functional connectivity between frontal 
cortical and striatal areas 
 
Dopamine receptor blockade did not 
prevent the MDPV-induced decrease in 
functional connectivity.  
Gannon, B.M. 




MDPV 0.01, 0.03, 
0.10, 0.30, 1, 








S(+)-MDPV was most potent to fully 
substitution for the cocaine training 
dose 
↑Locomotion after doses of S(+)-MDPV 
and racemic MDPV 
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López-Arnau, 





















↓ densities of dopamine and serotonin 
transporters without microgliosis 
 
↓ expression of tyrosine hydroxylase 
and tryptophan hydroxylase 2. 
impairment of the reference memory in 
the Morris water maze 
Kiyatkin, E.A. 









1, 3, and 9 
mg/kg (s.c) 











Methylone and MDPV dose-









Mephedrone 1 or 10 μM Flatworm 
planaria 





↑ preference to cocaine at both 1 and 
10 μM 
↓ locomotion after Mephedrone 
withdrawal 
Lopez-Arnau, 




















Adam, A. et 
al., 2014 (91) 
10.1016/j.neur
o.2014.07.004 
MDPV 10 mg/kg Male and 
female mice 
C57 
















 Male  mice 
C57BL/6J 













Mephedrone 0.3-30 µM Male Wistar 
rats  





Displaced RTI-121 and caused reverse 
transport of DA 
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Simmler, L.D. 






















All the cathinones were potent NA 
uptake inhibitors but different in DA vs 
5-HT 
None of the cathinones bound to 








8 weeks  Locomotion 
Microdialysis 
↑ release of DA & locomotion 
Marusich, J.A. 

































α-PVP is a potent uptake blocker at 
dopamine and norepinephrine 
transporters 
α-PBP and α-PPP are also 
catecholamine transporter blockers but 
display reduced potency 
↑ locomotor activity with all of them 
Watterson, 









1, 3, 10, 30, 
mg/kg 












↑ intracranial self-stimulation 
threshold reductions similar to that of 
methamphetamine 
 
Bonano, J.S. et 









0.32, 1 and 
3.2 










Methcathinone was the most potent 
compound, and MDPV was the longest 
acting compound 
 
Gregg, R.A. et 


















↑ cocaine-induced locomotor 
activation by prior MEPH exposure 
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Gregg, R.A. et 




















↑ repetitive movement by MEPH 
challenge compared to acute MEPH 
exposure in both paradigms 
 
Gatch, M.B. et 













1, 3, 10 or 30 
mg/kg 
0.3, 1, 3, 10 
or 30 mg/kg 







 Locomotor activity 
Discriminative Stimulus Effects 
 
MDPV and naphyrone produced 
locomotor stimulant effects that lasted 
much longer than cocaine or 
methamphetamine 
All compounds fully substituted for the 
discriminative stimulus effects of 
cocaine and methamphetamine 
Cameron, K. 

















mephedrone is a dopamine releasing 
agent and MDPV behave as a cocaine-
like reuptake inhibitor of dopamine. 
 
Baumann, 


















300 - 400 g 















↑ amplitude of the dopamine signal 
↑ extracellular concentrations of 
dopamine in the nucleus accumbens 

































↓ working memory with MEPH 
↑ body temperature 
 ↓ 5-HT levels in the frontal cortex, 
striatum and hippocampus with 
Methylone 
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Lopez-Arnau, 





Methylone 10-30 mg/kg 
(i.v or oral) 
Male Sprague-
Dawley rats 
225 - 250 g  Locomotion 
+ PK analysis 
↑locomotion 
Cozzi, N.V. et 


















300 – 350 g Human 
platelets 
HEK293 cells 









↑ uptake inhibition and release with 3-
TFMAP and 4–TFMAP at SERT compared 
with methcathinone 
↑ 5-HT extracellular level with 4-
TFMAP but doesn’t affect the locomotor 
activity 









3, 5, 10, 30 






225 – 275 g 






↑ ambulatory activity in rats and was 
inhibited by pretreatment with SCH 
23390 and enhanced by pretreatment 
with sulpiride 
↑ CPP by MEPH 
Meng, H. et 


















↑HR & ↑BP 
Baumann, 
M.H. et al., 








0.3 and 1.0 
mg/kg 












Mephedrone and Methylone similar to 
MDMA in potency and selectivity for 
monoamine transporters. 
↑ extracellular DA and 5-HT levels after 
Mephedrone and Methylone i.v 
administration in accumbens 
↑ Locomotor activity and stereotypy 
after 1mg/kg Mephedrone dose 
↑ Locomotor activity after 0.3mg/kg 
and 1mg/kg Methylone doses.  
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Table 1. Pre-clinical studies examining cathinone NPS pharmacology. The most recent manuscripts are presented first. DA = dopamine, NA = 
noradrenaline, DAT = dopamine transporter, NET = noradrenaline transporter, SERT = serotonin transporter, ICSS = intraccranial self-
stimulation, USV = ultrasonic vocalisation, CPP = conditioned place preference, MEPH = mephedrone, HR = heart rate, BP = blood pressure.  
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Table 2. Stimulants 




Age Sample Assay Main results 















4,4'-DMAR potently inhibited all monoamine 
transporters. 
4-MAR preferentially inhibited the NE and DA 
transporter 
3,4-DMAR only weakly inhibited the NE 
transporter 
Cai, W.T. et 




Methiopropamine 5 mg/kg (i.p) Rats  Nucleus 
accumbens 
 ↑number of total spine density 

































↓ uptake mediated by human DAT, NET or 
SERT 
Release assays identified 4,4'-DMAR as a 
substrate type releaser, capable of inducing 
transporter-mediated reverse transport via 
DAT, NET and SERT 
 ↓ rat and human isoforms of VMAT2 at a 
potency like MDMA 
Davidson, C. 






1, 10 and 100 









 Fast cyclic 
voltammetry 
(DA and NA) 
↑ evoked dopamine and noradrenaline efflux 
with Methylphenidate (10 μM)  
↑ evoked dopamine and noradrenaline efflux 
with 3,4-CTMP (0.1 and 1 μM)  
↑ evoked dopamine and noradrenaline efflux 
with Ethylphenidate (1 μM) 
Page | 41  
 































↑ inhibition NAT and DAT with all the drugs 
No cytotoxicity was observed after drug 
treatment at assay concentrations. 
McLaughlin,G























2‐MPM and 3‐MPM will exhibit stimulant 
properties like the parent compound 
phenmetrazine, whereas 4‐MPM may display 
entactogen properties more similar to MDMA. 
 
Zwartsen, A. 























↓ the weighted mean firing rate and weighted 
mean burst rate 
Mayer, F.P. 
















2-, 3- and 4-FPM inhibit uptake mediated by 
DAT and NET  
 







Patch clamp All FPM raised concentration-dependent 
release of monoamines from rat brain 
synaptosomes 
Sahai, M.A. 























5-MAPB reduces the rate of dopamine reuptake 
5-MAPB binds to the DAT and displace RTI-121 
as DAT ligand 
Shimshoni, 





















Good safety profile in rats at 10 and 30mg/kg 
Cytotoxic effect at 500 and 
1000mg/L concentrations 
McLaughlin, 















↑ potencies determined for blockage of 
dopamine uptake and norepinephrine uptake 
in (±)-threo isomer 
↓ potent at the dopamine transporter and 
norepinephrine transporter in MPH  















↑ sensitized locomotor activity the group that 
was pre-exposed at 5mg/kg of MPA 
 
MPA-induced locomotor sensitization was 
inhibited by a pre-injection of a dopamine D2 
receptor antagonist 
Marusich, 



























5-IT displayed greater potency for 
release at DAT over SERT, while 6-
IT displayed greater potency for 
release at SERT over DAT 











10 pM to 10 
μM 




Species differences in activity at TAAR1 among 
the highly active ligands, with a rank order of 
rat > mouse > human 































5F-ADB significantly increase the spontaneous 









N-Benzylpiperazine 0.1, 0.3, 1, 3, 
10, 30, 100, 
300, and 1000 
μg/ml 
10, 30, 100, 
and 300 μg/ml 









↑ LDH levels ↑ mitochondrial membrane 
potential, ↓ ATP and ↑ ROS production, ↑ 
levels of DNA damage marker (8-OHdG) and 
activation of caspases: -3 and -9. 
 
 
















625, 210 and 
0.5 µM for BZP 
35, 12 and 0.5 
µM for TFMPP 
522, 175 and 
0.5 µM for 
MeOPP 
467, 160 and 










Key enzymes of cholesterol biosynthesis, 
glycoprotein transmembrane nmb and fatty 
acid desaturase 1 were up-regulated by all four 
piperazine drugs 
The betaine-homocysteine-S-methyltransferase 
2 were down-regulated all four piperazine 
derivatives 
 












500 or 1000 
μM BZP 
 
5, 50 or 100 
μM TFMPP 





1-(3-trifluoromethylphenyl) piperazine was the 
most cytotoxic 
 









250 or 500 μM 
MeOPP or 
MDBP 





















↑dose-dependent manner, locomotor activity  
dose-dependent hypothermic response to 4-MA 

















↑ 5-HT properties in 4-methyl, 4-ethyl, and 4-





pyrrolidinobutiophenone potently inhibited the 
NET and DAT but not the SERT 
McLaughlin, 













More efficacious than MDMA 

























TFMPP seems to be the most potent cytotoxic 
compound 
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Brandt, S.D. 















↑ release of DA, NA, 5-HT. more potent than 
AMPH at 5-HT 
Dawson, P. 





















Displaced both DAT and 5-HT2 ligands and ↑ 
DA efflux. ↑ contraction in fundus and aorta 
Davidson, C. 













Bigger increase in DA vs cocaine 
 
Table 2. Pre-clinical studies examining stimulant NPS pharmacology. The most recent manuscripts are presented first. DA = dopamine, NA = 
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Table 3. synthetic cannabinoids 
Study DOI NPS Dose/conc Species/sex Age Sample Assay Main results 




AKB48 0.25 mg/kg to 
3 mg/kg 






↑ DA release in the nucleus accumbens 
shell at 0.25 mg/kg  
↓ startle/pre-pulse inhibition response 
at 3mg/kg  
↑ hypothermia, analgesia, and 
catalepsy at 3mg/kg  
↑impaired place preference and 
hypolocomotion at 0.5mg/kg 
Banister, S.D. 










0.1, 0.3, 1, and 
3 mg/kg (i.p) 
Male C57BL/6 
J mice 














compounds were potent CB1 agonists 
5F‐CUMYL‐P7AICA induced 
hypothermia 















↑inhibition of CYP3A4 and 
UGT1A9 activities 
Kevin, R.C. et 






















Potent CB1 receptor agonist 
↑ pro-convulsant effects at 0.3 mg/kg 






Domoto, M. et 
al., 2018 (135) 
10.1007/s0021
3-018-4933-5 
5F-AMB 300 nM Male and 
female 
C57BL/6J mice 
4−6 weeks Medial 
Prefrontal 
cortex 
Patch-clamp ↓ excitatory and inhibitory 
transmission in mPFC L5 pyramidal 
neurons via the activation of CB1 
receptors located in presynaptic 
terminals 
 
De Luca, M.A. 





















200 – 300 g 










5F-AKB-48 and STS-135 had higher Ki for 
CB1 binding. 
 ↑ DA in the accumbens shell with all 
the compounds 


































 JWH-030 was more cytotoxic than 
JWH-210, JWH-250 and RCS4 
 JWH-030 to block the hERG channel  
JWH-030 significantly reduced the APD 
at 90% repolarization 














1-30 µM for 
0.5-3 h 
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Table 3. Pre-clinical studies examining synthetic cannabinoid receptor agonist NPS pharmacology. The most recent manuscripts are presented 
first. DA = dopamine, NA = noradrenaline, DAT = dopamine transporter, NET = noradrenaline transporter, SERT = serotonin transporter. 
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Table 4. Other NPS 
Study DOI NPS Dose/conc Species/sex Age Sample Assay Main results 
Luethi, D. et 






   Human cells Monoamine 
transporter 
assays 
2C-BI-8 and 2C-BI-12 activated 
serotonin 5-HT2A and 5-HT2B 
receptors at submicromolar 
concentrations 
Wallach, J. et 




















↑affinity for NMDA receptors 
↓ long-term potentiation 
↓NMDA receptor-induced field 
excitatory postsynaptic potentials 
↓ PPI 
Costa, G. et 







i.p., × 5 days 




Pre-treatment with MXE impair 
alterations in the elevated plus maze, 
marble burying and novel object 
↑ neurotoxicity 
Yoon, K.S. et 





0.1–500 μM Mice  H9c2 cells Cytotoxic 
assays 
↓ cell viability and PAK-1 mRNA levels 
at 10 μM 
↓beating rate of primary 
cardiomyocytes at 100 μM 
Halberstadt,A.











 C57BL/6J mice   Head twitch 
response 
(HTR) assay 
DOB and 2C-B induced the HTR 
↑potency of DOB-DFLY and 2C-B-DFLY 
than DOB and 2C-B 
2C-I-FLY, 2C-E-FLY and 2C-EF-FLY 
active in the HTR assay but had low 
potency 
Herian, M. et 
al., 2019 (144) 
10.1007/s1264
0-019-00033-x 




280 – 350 g Frontal cortex Microdialysis Inverted U-shaped dose-response 
curve on extracellular DA and 5-HT 
levels 
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U-shaped dose-response curve on GLU 
levels  
Zwartsen, A. 





















↓ the weighted mean firing rate and 
weighted mean burst rate 
Shintani-
Ishida, K. et 
al., 2018 (145) 
10.1111/1556-
4029.13583 
25B-NBOMe i.p. 0.5 mg/kg Male Sprague-
Dawley rats 





HPLC ↑ 25B-NBOMe concentration in blood 
samples after 6 hours 
25B-NBOMe accumulated primarily in 
the lung 










DOC: 0.1, 0.3, 
and 0.5 mg/kg 
AH-7921: 0.1, 





180 – 220 g 
 
 






↑ preference with both drugs at 0.3 
mg/kg  
↑ number of responses to the active 
lever in the self-administration test at 
0.01 mg/kg 
Luethi, D. et 
















Diclofensine bound to adrenergic, 
dopamine, serotonin, and trace 
amine-associated receptors. 
Diphenidine bound to adrenergic 
α1A and α2A receptors and serotonin 5-
hydroxytryptamine 1A (5-HT1A) and 5-
HT2A receptors. 
Methoxphenidine bound to adrenergic 
α2A and serotonin 5-HT2A and 5-HT2C 
receptors 
         
Hondebrink, L. 




















↑ the glutamate-evoked increase in 
[Ca2+] in rat primary cortical cells with 
10 μM methoxetamine 
 













↓ the K+- and acetylcholine-evoked 
increase in [Ca2+]I  in human SH-SY5Y 
cells with 10 μM methoxetamine 
 
↓ spontaneous neural activity 
between 10-100μM methoxetamine 
↓ uptake via monoamine transporters 
(DAT, NET and SERT) 












3 – 10 weeks Whole rat 
brain 












Patch clamp  
Ephenidine acts at the PCP site of the 
NMDA receptor and has lower affinity 
for the dopamine and noradrenaline 
transporters 
 
↑ inhibition of the NMDA receptor 
mediated fEPSP at 10 μM 
10 μM blocked NMDA receptor-
mediated EPSCs 
Rickli, A. et 















    Monoamine 
transporter 
assay 
↓ binding 5-HT2A with all the 
tryptamines and psilocin and DMT 
compared with LSD 
DMT, DiPT, 4-OH-DiPT, and 4-OH-MET, 
interacted partially with the 
norepinephrine transporter 
LSD but not the tryptamines 
interacted with adrenergic and 
dopaminergic receptors 
Wallach, J. et 



















9 - 10 weeks 





Monoamine Reuptake Inhibition 
Assays 
In-vitro Field Excitatory Postsynaptic 
potential 
DPH and 2-MXP, were found to be 
rel tively selective NMDAR 
antagonists and inhibited NMDAR 
mediated 
field EPSPs 





 Pre-pulse inhibition 
 
DPH and 2-MXP significantly inhibited 
PPI 
Rickli, A. et 




2C drugs    Human cells Monoamine 
transporter 
assay 
NBOMe drugs were very potent 5-
HT2A receptor agonists 
2C drugs increased the binding affinity 
at serotonergic 5-HT2A, 5-HT2C, 
adrenergic α1, dopaminergic D1-3, 
and histaminergic H1 receptors and 
monoamine transporters but reduced 
binding to 5-HT1A receptors and 
TAAR1 
Blough, B.E. et 










All tryptamines were 5-HT2A agonists. 
N-ethyltryptamine was the greatest 5-
HT releaser and 5-MeO-MIPT was the 
weakest 5-HT uptake inhibitor. 
Dargan, P.I. et 






i.p 30 mg/kg x 
3 months  
Mice 2-5 months Bladder and 
kidneys 
CD4 & Sirius 
red staining 
Bladder and renal toxicity 
Paulke, A. et 






    In silico and 
radioligand 
assays 
Lower affinity than LSD but clear 
affinity at 5-HT1A, 5-HT2, and α2 
Compton, 





5-MeO-DIPT 6 x 5 or 20 
mg/kg 
Male Long 
Evans rats   
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Table 4. Pre-clinical studies examining ‘other’ NPS pharmacology. The most recent manuscripts are presented first. DA = dopamine, NA = 
noradrenaline, DAT = dopamine transporter, NET = noradrenaline transporter, SERT = serotonin transporter, PPI = pre-pulse inhibition. 
 
